Epidemic Keratoconjunctivitis Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Epidemic Keratoconjunctivitis Epidemiology Forecast Report Coverage

Expert Market Research's “Epidemic Keratoconjunctivitis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of epidemic keratoconjunctivitis. It projects the future incidence and prevalence rates of epidemic keratoconjunctivitis cases across various populations. The study covers age, gender, and type as major determinants of the epidemic keratoconjunctivitis population. The report highlights patterns in the prevalence of epidemic keratoconjunctivitis over time and projects future trends based on multiple variables.

Epidemic Keratoconjunctivitis Understanding: Disease Overview

Epidemic keratoconjunctivitis (EKC) is a highly contagious viral infection affecting the cornea and conjunctiva of the eye. It is primarily caused by adenoviruses, which are transmitted through direct contact with infected secretions, contaminated surfaces, or medical instruments. It manifests symptoms such as redness, watery discharge, photophobia, and blurred vision. The disease can vary in severity and typically progresses through acute, subacute, and chronic phases. EKC is categorized into several types based on viral serotypes, including types 8, 19, and 37, which are most associated with large outbreaks and rapid community transmission.

Epidemic Keratoconjunctivitis Epidemiology Perspective

The epidemic keratoconjunctivitis epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the epidemic keratoconjunctivitis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for epidemic keratoconjunctivitis and its trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Mohan, Amit et al., 2024, a hospital-based study in North India reported 387 cases of epidemic keratoconjunctivitis (EKC) among 2,876 patients, representing a prevalence rate of 13.45%. The mean age of patients was 30.69 years, with the youngest being 3 months old and the oldest 71 years, demonstrating that the disease can affect all age groups.
• The study also highlighted gender differences, with 70.8% of cases in men and 29.2% in women, indicating a higher prevalence among males during the 2023 outbreak. These findings emphasize the widespread susceptibility of epidemic keratoconjunctivitis across ages and genders, underlining the importance of early detection and targeted preventive strategies in both children and adults.
• In England, adenovirus positivity reached 1.7% among tested respiratory specimens, with rates up to 9.9% in children under 5 years, demonstrating active circulation of adenovirus in the UK population.
• An outbreak investigation in Los Angeles, United States, identified 17 cases of epidemic keratoconjunctivitis linked to a single eye-care clinic, with transmission associated with inadequate disinfection of ophthalmic instruments and contaminated eye drops.

Read more about this report - Request a Free Sample

Country-wise Epidemic Keratoconjunctivitis Epidemiology

The epidemic keratoconjunctivitis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Epidemic keratoconjunctivitis (EKC) demonstrates significant regional incidence across key global markets. According to Vahidreza Afrasiabi et al., 2023, approximately 1% of all doctor visits in the United States are related to conjunctivitis, with viral infections, particularly adenovirus, accounting for 65–90% of cases. In Japan, Tetsuaya Muto et al., 2023, report that nearly one million individuals contract epidemic keratoconjunctivitis annually. Similarly, during a localized outbreak in Northern India, Shalini Kumari et al., 2025, observed 35–50 ophthalmology outpatient visits per day, with 75–90% diagnosed with epidemic keratoconjunctivitis. These trends highlight the substantial clinical burden of the disease across different regions.

Epidemic Keratoconjunctivitis: Treatment Overview

Epidemic keratoconjunctivitis treatment primarily focuses on symptomatic relief and preventing the spread of infection. There is no specific antiviral therapy for epidemic keratoconjunctivitis. Management includes the use of lubricating eye drops, cold compresses, and topical anti-inflammatory medications to reduce discomfort and inflammation. In severe cases, corticosteroid eye drops may be prescribed under strict medical supervision to control corneal involvement. Maintaining strict hygiene practices, including frequent handwashing, avoiding contact lens use, and disinfecting contaminated surfaces, is crucial to limit transmission. Recovery typically occurs within two to three weeks, though some patients may experience prolonged visual disturbances.

Key Questions Answered

• What are the key findings of epidemic keratoconjunctivitis epidemiology in the 8 major markets?
• What will be the total number of patients with epidemic keratoconjunctivitis across the 8 major markets during the forecast period?
• What was the country-wise epidemic keratoconjunctivitis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of epidemic keratoconjunctivitis patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of epidemic keratoconjunctivitis during the forecast period of 2026-2035?
• What are the currently available treatments for epidemic keratoconjunctivitis?
• What are the disease risks, signs, symptoms, and unmet needs of epidemic keratoconjunctivitis?

Scope of the Epidemic Keratoconjunctivitis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of epidemic keratoconjunctivitis based on several factors.
• Epidemic keratoconjunctivitis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The epidemic keratoconjunctivitis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Vernal Keratoconjunctivitis Market

Allergic Conjunctivitis Pipeline Analysis Report